Abstract：Objective To investigate the clinical effect of tirofiban combined with percutaneous coronary intervention (PCI) in the treatment of acute myocardial infarction (AMI). Methods From March 2016 to March 2018, 84 patients with AMI were randomly divided into a control group (n=42) and a trial group (n=42). The control group was treated with PCI, and the trial group was treated with tirofiban combined with PCI, and the cardiac function, cardiac markers, and the incidence of cardiovascular adverse reactions were investigated and compared between two groups. Results The left ventricular ejection fraction (LVEF) in the trial group was higher than that in the control group . The left ventricular end-diastolic diameter (LVEDD) , creatine kinase isoenzyme (CK-MB) , and troponin I (cTnI) in the trial group were lower than those in the control group (all P<0.05). The incidence of cardiovascular adverse reactions in the trial group was 9.52% (4/42), which was significantly lower than that in the control group (28.57%, 12/42) (χ2=4.941, P<0.05). Conclusion Tirofiban combined with PCI is effective in the treatment of AMI, which can effectively improve the cardiac function and the levels of cardiac markers, and reduce the total incidence of cardiovascular adverse reactions.
崔勇波. 替罗非班联合经皮冠脉介入术治疗急性心肌梗死的临床效果分析[J]. 中国校医, 2020, 34(9): 671-672,688.
CUI Yong-bo. Clinical effect of tirofiban combined with percutaneous coronary intervention in treatment of acute myocardial infarction. Chinese Journal of School Doctor, 2020, 34(9): 671-672,688.
2020, Vol. 34 
